Additionally, improving CAR-T biological efficiency could reduce dosing needs, further cutting costs and expanding access.

Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The "2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA" report has been added to ResearchAndMarkets ...

The COVID-19 pandemic has bit into sales at Novartis ... Results also showed a strong launch for its rare diseases gene therapy, Zolgensma, which is now approved for the muscle wasting disease ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team.

Following CORDStrom TM, INmune Bio plans to transition production of INKmune ®, its NK-priming cell medicine for solid tumors, to the same facility, supporting ongoing and future trials in the US and ...

It also follows the decision by gene therapy pioneer bluebird bio to sell itself to private equity companies for a bargain price after struggling to build sales momentum for its three FDA-approved ...

Both marketed therapies are prescribed when a patient has shown an inadequate response to at least one conventional or biologic therapy. Currently, there are only two cell and gene therapies (CGTs ...

Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of sickle cell gene therapy ...